319 related articles for article (PubMed ID: 30317986)
1. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
Tsouka AN; Tellis CC; Tselepis AD
Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
4. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
6. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
Wang Y; Liu ZP
Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
Bittner VA; Giugliano RP; Brinton EA; Guyton JR
J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibitors in the prevention of cardiovascular disease.
Latimer J; Batty JA; Neely RD; Kunadian V
J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives.
Fitzgerald G; Kiernan T
Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908
[TBL] [Abstract][Full Text] [Related]
11. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
Alkhalil M
Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
14. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
16. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
Wallemacq C
Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
[TBL] [Abstract][Full Text] [Related]
17. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
Chen B; Shi X; Cui Y; Hou A; Zhao P
Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268
[TBL] [Abstract][Full Text] [Related]
18. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
20. A review of PCSK9 inhibition and its effects beyond LDL receptors.
Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A
J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]